Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MENAC: Multimodal Intervention for Cancer Cachexia
NCT02330926Phase 3Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Apr 2015
- Primary completion
- Apr 2023
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of ibuprofen in cancer cachexia (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: Change in body weight at 6 weeks. Started Apr 2015; status: completed.
02
Drugs
ibuprofen
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT02330926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02330926.